Cite
Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.
MLA
Chou, W. C., et al. “Clinical Implications of Minimal Residual Disease Monitoring by Quantitative Polymerase Chain Reaction in Acute Myeloid Leukemia Patients Bearing Nucleophosmin (NPM1) Mutations.” Leukemia (08876924), vol. 21, no. 5, May 2007, pp. 998–1004. EBSCOhost, https://doi.org/10.1038/sj.leu.2404637.
APA
Chou, W.-C., Tang, J.-L., Wu, S.-J., Tsay, W., Yao, M., Huang, S.-Y., Huang, K.-C., Chen, C.-Y., Huang, C.-F., & Tien, H.-F. (2007). Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia (08876924), 21(5), 998–1004. https://doi.org/10.1038/sj.leu.2404637
Chicago
Chou, W.-C., J.-L. Tang, S.-J. Wu, W. Tsay, M. Yao, S.-Y. Huang, K.-C. Huang, C.-Y. Chen, C.-F. Huang, and H.-F. Tien. 2007. “Clinical Implications of Minimal Residual Disease Monitoring by Quantitative Polymerase Chain Reaction in Acute Myeloid Leukemia Patients Bearing Nucleophosmin (NPM1) Mutations.” Leukemia (08876924) 21 (5): 998–1004. doi:10.1038/sj.leu.2404637.